Mereo BioPharma Group plc (MREO) return on equity (ROE)
Mereo BioPharma Group plc (MREO) earned a return on equity of -102.4% in fiscal 2025 (the year ended December 31, 2025). That is 31.4 percentage points lower than the -70.9% of fiscal 2024. Figures as of 18 Nov 2026, 09:07 UTC, from Yahoo Finance.
Key facts
- Return on equity, fiscal 2025
- -102.4%
- Change on fiscal 2024
- −31.4 pts
- Highest on record
- -58.3%fiscal 2023
- Lowest on record
- -102.4%fiscal 2025
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Figures, not advice.
Mereo BioPharma Group plc return on equity (ROE), in more detail
Across the 4 fiscal years on record (2022–2025), the highest was -58.3% in fiscal 2023 and the lowest -102.4% in fiscal 2025. The fiscal 2025 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is -70.9%.
Return on equity by fiscal year
Mereo BioPharma Group plc return on equity (ROE), year by year
| Fiscal year | Return on equity | Change | Year ended |
|---|---|---|---|
| 2025 | -102.4% | 31.4 pts down | |
| 2024 | -70.9% | 12.6 pts down | |
| 2023 | -58.3% | 23.8 pts up | |
| 2022 | -82.1% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
How to read it
It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.
Mereo BioPharma Group plc, figure by figure
- Mereo BioPharma Group plc market cap
- Mereo BioPharma Group plc revenue
- Mereo BioPharma Group plc earnings
- Mereo BioPharma Group plc earnings per share (EPS)
- Mereo BioPharma Group plc P/E ratio
- Mereo BioPharma Group plc P/S ratio
- Mereo BioPharma Group plc P/B ratio
- Mereo BioPharma Group plc free cash flow
- Mereo BioPharma Group plc operating margin
- Mereo BioPharma Group plc dividend
- Mereo BioPharma Group plc shares outstanding
- Mereo BioPharma Group plc total debt
- Mereo BioPharma Group plc cash on hand
- Mereo BioPharma Group plc total assets
- Mereo BioPharma Group plc return on invested capital (ROIC)
Mereo BioPharma Group plc (MREO) overview: price, valuation and scorecard
Mereo BioPharma Group plc return on equity (ROE): questions and answers
What is Mereo BioPharma Group plc's return on equity?
Mereo BioPharma Group plc (MREO) earned a return on equity of -102.4% in fiscal 2025 (the year ended December 31, 2025). That is 31.4 percentage points lower than the -70.9% of fiscal 2024.
Is Mereo BioPharma Group plc's return on equity high or low compared with its own history?
The fiscal 2025 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is -70.9%.
What are the highest and lowest return on equity figures on record for Mereo BioPharma Group plc?
Across the 4 fiscal years on record (2022–2025), the highest was -58.3% in fiscal 2023 and the lowest -102.4% in fiscal 2025.
How is Mereo BioPharma Group plc's return on equity calculated?
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative. For Mereo BioPharma Group plc it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: return on equity (ROE)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Mereo BioPharma Group plc (MREO) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/MREO/roe
Underlying data: Yahoo Finance.